Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boevé LM, Hulshof MC, Vis AN, Zwinderman AH, Twisk JW, Witjes WP, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75:410–8.

Article  PubMed  Google Scholar 

Schröder F, Crawford E, Axcrona K, Payne H, Keane T. Androgen deprivation therapy: past, present and future. BJU Int. 2012;109:1–12.

Article  PubMed  Google Scholar 

Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4:365.

PubMed  PubMed Central  Google Scholar 

Montgomery B, Cheng HH, Drechsler J, Mostaghel EA. Glucocorticoids and prostate cancer treatment: friend or foe? Asian J Androl. 2014;16:354.

Article  PubMed  PubMed Central  Google Scholar 

Sakellakis M, Flores LJ. Is the glucocorticoid receptor a key player in prostate cancer?: A literature review. Medicine. 2022;101:e29716.

Article  PubMed  PubMed Central  Google Scholar 

Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Alyamani M, Zhang A, Chang KH, Berk M, Li Z et al. Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. Elife. 2017;6:e20183.

Vellky JE, Ricke WA. Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia. 2020;22:566–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Formaggio N, Rubin MA, Theurillat J-P. Loss and revival of androgen receptor signaling in advanced prostate cancer. Oncogene. 2021;40:1205–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen S-Y, Wang J, Yu G-Q, Liu W, Pearce D. Androgen and glucocorticoid receptor heterodimer formation: a possible mechanism for mutual inhibition of transcriptional activity. J Biol Chem. 1997;272:14087–92.

Article  CAS  PubMed  Google Scholar 

Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, et al. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer. 2015;136:E27–38.

Article  CAS  PubMed  Google Scholar 

Valle S, Sharifi N. Targeting Glucocorticoid Metabolism in Prostate Cancer. Endocrinology. 2021;162:bqab132.

Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A, et al. Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2022;28:1549–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirayama Y, Sadar MD. Does increased expression of glucocorticoid receptor support application of antagonists to this receptor for the treatment of castration resistant prostate cancer? AME Med J. 2018;3:66.

Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017;6:27861.001.

Puhr M, Hoefer J, Eigentler A, Ploner C, Handle F, Schaefer G, et al. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. Clin Cancer Res. 2018;24:927–38.

Article  CAS  PubMed  Google Scholar 

Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, et al. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012;72:157–64.

Article  CAS  PubMed  Google Scholar 

Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014;5:72–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sahu B, Laakso M, Pihlajamaa P, Ovaska K, Sinielnikov I, Hautaniemi S, et al. FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer CellsAR and GR Cistromes in Prostate Cancer Cells. Cancer Res. 2013;73:1570–80.

Article  CAS  PubMed  Google Scholar 

Narayanan S, Srinivas S, Feldman D. Androgen–glucocorticoid interactions in the era of novel prostate cancer therapy. Nat Rev Urol. 2016;13:47–60.

Article  CAS  PubMed  Google Scholar 

Molitch ME. Glucocorticoid receptor blockers. Pituitary. 2022;25:733–6.

Article  CAS  PubMed  Google Scholar 

Kach J, Conzen SD, Szmulewitz RZ. Targeting the glucocorticoid receptor in breast and prostate cancers. Sci Transl Med. 2015;7:305ps319.

Article  Google Scholar 

Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, et al. A phase II study of mifepristone (RU‐486) in castration‐resistant prostate cancer, with a correlative assessment of androgen‐related hormones. BJU Int. 2008;101:1084–9.

Article  CAS  PubMed  Google Scholar 

Nandana S, Tripathi M, Duan P, Chu CY, Mishra R, Liu C, et al. Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis. Cancer Res. 2017;77:1331–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel GK, Dutta S, Syed MM, Ramachandran S, Sharma M, Rajamanickam V, et al. TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p. Cancers. 2021;13:5020.

Abrahams A, Parker MI, Prince S. The T‐box transcription factor Tbx2: its role in development and possible implication in cancer. IUBMB Life. 2010;62:92–102.

Article  CAS  PubMed  Google Scholar 

Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, et al. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell. 2020;37:584–98. e511.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McIntyre AJ, Angel CZ, Smith JS, Templeman A, Beattie K, Beattie S, et al. TBX2 acts as a potent transcriptional silencer of tumour suppressor genes through interaction with the CoREST complex to sustain the proliferation of breast cancers. Nucleic Acids Res. 2022;50:6154–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vance KW, Carreira S, Brosch G, Goding CR. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res. 2005;65:2260–8.

Article  CAS  PubMed  Google Scholar 

Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, et al. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011;71:1668–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Norris JD, Chang C-Y, Wittmann BM, Kunder RS, Cui H, Fan D, et al. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell. 2009;36:405–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang B, Lindley LE, Fernandez-Vega V, Rieger ME, Sims AH, Briegel KJ. The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells. PLoS One. 2012;7:e41355.

Article  CAS